ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features

MRIdian A3i and Brain Treatment Package Enhance On-Table Adaptive Workflow and Expand Clinical Utility CLEVELAND, Dec. 15, 2021 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company received FDA 510(... Devices, Oncology, FDA ViewRay, MRIdian, MRI-guided radiation therapy, MRIdian A3i

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047319

Source: HSMN NewsFeed - December 15, 2021 Category: Pharmaceuticals Source Type: news